Specific markers to monitor: fasting glycemia, HbA1c, cortisol, cortisol / DHEA ratio, nitrogen balance, and body composition (preserved lean mass vs reduced fat mass, ratio visualized by DEXA)
In a cohort of 3731 patients, weight loss of 5%, 10%, and 15% was observed in 63%, 33%, and 14%, respectively, after 56 weeks of treatment (27%, 11%, and 4% with placebo),69 or of an additional 6% at 56 weeks in patients who had already lost 6% through hypocaloric diet and exercise.70 Positive results were also observed in adolescent patients with obesity,71 and in real-life studies substantial weight loss has also been reported.7275 Phase 3 trials with GLP-1 receptor agonists indicated specifically for obesity and overweight
Esophageal and small bowel obstruction from guar gum-containing "diet pills": analysis of 26 cases reported to the Food and Drug Administration
Exhaled carbon monoxide measurements Exhaled CO levels will be measured at baseline (week 0), week 12, and week 24
Several studies have evaluated weight regain after stopping GLP drugs
Its important to consult with a healthcare provider to ensure Semaglutide is appropriate for you, especially if you have a history of certain health conditions such as pancreatitis or thyroid cancer.
